Jefferies Financial Group Issues Positive Forecast for Cibus (NASDAQ:CBUS) Stock Price

Cibus (NASDAQ:CBUS) had its price objective raised by Jefferies Financial Group from $1.90 to $3.00 in a research note released on Wednesday morning,Benzinga reports. Jefferies Financial Group currently has a hold rating on the stock.

A number of other research analysts have also issued reports on CBUS. Weiss Ratings reissued a “sell (e+)” rating on shares of Cibus in a research note on Wednesday, January 21st. Canaccord Genuity Group reaffirmed a “buy” rating and set a $15.00 target price on shares of Cibus in a research note on Monday, December 8th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Cibus presently has a consensus rating of “Hold” and an average target price of $9.00.

Cibus Price Performance

Shares of CBUS opened at $2.87 on Wednesday. The company has a market cap of $155.78 million, a P/E ratio of -0.96 and a beta of 1.62. The stock has a fifty day moving average price of $2.70 and a 200 day moving average price of $1.94. The company has a debt-to-equity ratio of 1.37, a current ratio of 0.72 and a quick ratio of 0.72. Cibus has a 12 month low of $1.09 and a 12 month high of $4.19.

Cibus (NASDAQ:CBUS) last posted its earnings results on Tuesday, March 17th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.01. Cibus had a negative return on equity of 174.58% and a negative net margin of 3,492.30%.The company had revenue of $1.06 million for the quarter, compared to analysts’ expectations of $1.64 million. On average, research analysts forecast that Cibus will post -2.96 earnings per share for the current year.

Institutional Trading of Cibus

A number of institutional investors have recently made changes to their positions in CBUS. Bank of America Corp DE increased its stake in shares of Cibus by 113.4% during the fourth quarter. Bank of America Corp DE now owns 35,536 shares of the company’s stock valued at $99,000 after acquiring an additional 18,885 shares during the period. AQR Capital Management LLC acquired a new stake in Cibus in the first quarter worth approximately $73,000. Transce3nd LLC boosted its stake in Cibus by 29.1% during the 2nd quarter. Transce3nd LLC now owns 52,656 shares of the company’s stock valued at $75,000 after purchasing an additional 11,861 shares in the last quarter. Qube Research & Technologies Ltd bought a new position in Cibus during the 2nd quarter valued at $39,000. Finally, Raymond James Financial Inc. increased its position in shares of Cibus by 31.0% during the 2nd quarter. Raymond James Financial Inc. now owns 53,713 shares of the company’s stock valued at $74,000 after purchasing an additional 12,722 shares during the period. 33.81% of the stock is owned by institutional investors and hedge funds.

About Cibus

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.